A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats

Creative Commons License

DURAK A., OLĞAR Y., Degirmenci S., AKKUŞ E., TUNCAY E., Turan B.

CARDIOVASCULAR DIABETOLOGY, vol.17, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2018
  • Doi Number: 10.1186/s12933-018-0790-0
  • Journal Name: CARDIOVASCULAR DIABETOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Diabetes, SGLT2 inhibitors, Heart function, Electrophysiology, Oxidative stress, Insulin resistance, OXIDATIVE STRESS, NA+/H+ EXCHANGER, DYSFUNCTION, HEART, EMPAGLIFLOZIN, OBESITY, CARDIOMYOCYTES, MORTALITY, ZN2+, PATHOPHYSIOLOGY
  • Eskisehir Osmangazi University Affiliated: No

Abstract

Background: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect.